Schmid Timothy, EVP and Worldwide Chair of MedTech at Johnson & Johnson (JNJ), has demonstrated a consistent pattern of selling activity in the company’s stock, according to SEC Form 4 filings. Over 27 reported transactions, Schmid has sold $9.54 million worth of JNJ shares while purchasing $4.33 million, reflecting a net divestment trend. The most recent trades, all sales, occurred in February 2026, including a $3.25 million transaction on February 20 and two sales totaling $3.37 million on February 18. Earlier that month, Schmid also exercised options ("M" transactions) on February 6 and 15, acquiring shares worth $1.59 million and $1.17 million, respectively, though these were paired with sales shortly afterward.
The filings reveal that Schmid’s trading activity has been concentrated exclusively in JNJ, with no transactions in other companies. While some earlier transactions in 2024 included smaller option exercises and stock acquisitions, the overall direction since then has leaned toward reducing his position. Notably, the three most recent trades in February 2026 were outright sales, with no offsetting buys. The absence of recent purchases suggests a shift toward liquidity, though the sales could also reflect routine portfolio management given his executive role. The data does not indicate accumulation, with Schmid’s last recorded buy occurring prior to the 2024 transactions.
AI-assisted summary